Contact Information: Contact: The Global Consulting Group Rachel Levine T: (646) 284-9439 E:
Cleveland BioLabs to Present Protectan CBLB502 at 2007 BARDA Industry Day
Department of Defense RFP Decision Expected in Late 2007
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - July 25, 2007) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) (BOST : CBLI ) today announced that it will present its Protectan CBLB502 at the
2007 Biomedical Advanced Research and Development Authority (BARDA)
Industry Day, on August 3, in Washington, DC.
Cleveland BioLabs Director of Business Development, Alan Wolfman PhD., will
give a presentation discussing Protectan CBLB502 as both a protectant and
treatment for acute radiation syndrome (ARS) stemming from radiation
exposure. The presentation will focus on the most recent research progress
demonstrating CBLB502's effectiveness in treating both hematopoietic and
gastrointestinal syndromes. The presentation will also highlight
developmental aspects of Protectan CBLB502 indicating that it can be
rapidly produced and stockpiled as the most versatile compound addressing
ARS.
Earlier this year, Cleveland BioLabs submitted Protectan CBLB502 to the
Department of Defense (DoD) in response to a Request for Proposal (RFP) for
medical radiation countermeasures to treat gastrointestinal effects of ARS.
The DOD RFP award would provide funding for development of the
countermeasure through FDA approval, as well as a commitment to purchase up
to 500,000 doses, thereafter.
Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland
BioLabs, stated, "We look forward to sharing Protectan CBLB502's recent
development progress at the BARDA forum. CBLB502's unique abilities to
mitigate the damaging effects of radiation on the gastrointestinal system
as well as demonstrate significant survival benefits are a breakthrough in
this field of study. We believe that CBLB502 presents the best solution
for the DoD's requirements and expect the DoD to make its decision on the
RFP later this year."
The goal of the BARDA industry Day is to provide an open forum for
companies interested in working with the Federal Government to showcase
technological advances in medical countermeasures to manmade and naturally
occurring threats. Presenters will demonstrate the progress of current
activities in advanced research and development of medical countermeasures
that will contribute to the success of the HHS Pandemic Influenza Plan,
Project BioShield, BARDA, and the HHS Public Health Emergency Medical
Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death to treat
cancer and protect normal tissues from exposure to radiation and other
stresses. The Company has strategic partnerships with the Cleveland Clinic
Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the
Armed Forces Research Radiobiology Institute. To learn more about Cleveland
BioLabs, Inc., please visit the company's website at
http://www.cbiolabs.com.
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995.
Forward-looking statements reflect management's current expectations, as of
the date of this press release, and involve certain risks and
uncertainties. Our actual results could differ materially from those
anticipated in these
forward-looking statements as a result of various factors. Some of the
factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in our Registration Statement on Form SB-2/A filed
with the Securities and Exchange Commission on September 8, 2006.